A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

Prospective, Observational Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Patients With Hepatitis C in Georgia

This prospective observational study will investigate predictive values of virological response in pegylated interferon alfa-2a (Pegasys)/ribavirin (Copegus) treatment-naive participants with chronic hepatitis C. Participants will be treated with pegylated interferon alfa-2a and ribavirin as prescribed by the physician. Data will be collected for a maximum of 96 weeks.

Inclusion Criteria:

- Diagnosis of chronic hepatitis C infection

Exclusion Criteria:

• Co-infection with human immunodeficiency virus (HIV) and/or hepatitis B
• Participants previously treated with pegylated interferon alfa-2a/ribavirin
• Participation in another clinical study within 30 days prior to study start of ML25544